<DOC>
	<DOCNO>NCT00638495</DOCNO>
	<brief_summary>The efficacy safety TRK-820 evaluate treatment intractable pruritus patient Chronic Liver Disease administer 2.5 , 5 10 microg drug placebo 28 day four group design randomize , double-blind , parallel-group comparison . In addition , plasma concentration TRK-820 primary metabolite determine .</brief_summary>
	<brief_title>Phase II Study TRK-820 Soft Capsules — Intractable Pruritus Patients With Chronic Liver Disease —</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<criteria>Chronic Liver Disease present ; patient 's general condition judge physician stable prospect abrupt change pathophysiology . It confirm either follow treatment pruritus antihistamine antiallergics adequately effective patient : Malignant tumor Depression , integration dysfunction syndrome ( schizophrenia ) , dementia Hepatic encephalopathy , hepatic cirrhosis ascites esophageal gastric aneurysm control Alcoholic liver disease Atopic dermatitis , chronic urticaria , skin disease produce generalize pruritus judge physician affect assessment pruritus associate Chronic Liver Disease study Allergy opioid drug Drug dependence alcohol dependence Chronic renal failure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>